Highlight Therapeutics
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Dermatology
Highlight Therapeutics is a privately held biotech at a value inflection point. With Phase 2b data imminent, our validated dsRNA platform and lead asset BO-112 are poised to deliver the first broadly adoptable immunotherapy for Difficult-to-Treat Cutaneous Basal Cell Carcinoma — a disease affecting millions of patients with no approved non-surgical alternative.
The unmet need is substantial: over 5 million BCC lesions treated annually across the US and Europe, a growing burden falling predominantly on an aging population currently left with surgery as their only option. Beyond BCC, the platform carries demonstrated translational potential across skin tumors and broader solid oncology.
Company HQ City:
Paterna, Valencia
Company HQ State:
Spain
Company HQ Country:
Spain
Year Founded:
2013
Lead Product in Development:
BO112
CEO
Mercedes Diz
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
One
When you expect your next catalyst update?
3QTR 2026
What is your next catalyst (value inflection) update?
Phase 2b primary data readout
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}